

NIH Public Access

Author Manuscript

Biochemistry. Author manuscript; available in PMC 2012 October 18.

Published in final edited form as:

Biochemistry. 2011 October 18; 50(41): 8926–8936. doi:10.1021/bi201148a.

A Heme Peroxidase with a Functional Role as an L-Tyrosine Hydroxylase in the Biosynthesis of Anthramycin

Katherine L. Connor[†], Keri L. Colabroy[§], and Barbara Gerratana[†]

[†]Department of Chemistry and Biochemistry, University of Maryland, MD 20742, USA

[§]Department of Chemistry, Muhlenberg College, Allentown, PA 18014, USA

Abstract

We report the first characterization and classification of Orf13 (S. refuineus) as a heme dependent peroxidase catalyzing the *ortho*-hydroxylation of L-tyrosine to L-DOPA. The putative tyrosine hydroxylase coded by orf13 of the anthramycin biosynthesis gene cluster has been expressed and purified. Heme b has been identified as the required cofactor for catalysis and maximal L-tyrosine conversion to L-DOPA is observed in the presence of hydrogen peroxide. Pre-incubation of Ltyrosine with Orf13 prior to the addition of hydrogen peroxide is required for L-DOPA production. However, the enzyme becomes inactivated by hydrogen peroxide during catalysis. Steady state kinetic analysis of L-tyrosine hydroxylation revealed similar catalytic efficiency for both L-tyrosine and hydrogen peroxide. Spectroscopic data from a reduced-CO (g) UV-visible spectrum of Orf13 and electron paramagnetic resonance of ferric-heme Orf13 are consistent with heme peroxidases that have a histidyl-ligated heme-iron. Contrary to the classical heme peroxidase oxidation reaction with hydrogen peroxide that produces coupled aromatic products such as o, o'-dityrosine, Orf13 is novel in its ability to catalyze aromatic amino acid hydroxylation with hydrogen peroxide, in the substrate addition order and for its substrate specificity for L-tyrosine. Peroxygenase activity of Orf13 for the *ortho*-hydroxylation of L-tyrosine to L-DOPA by a molecular oxygen dependent pathway in the presence of dihydroxyfumaric acid is also observed. This reaction behavior is consistent with peroxygenase activity reported with horseradish peroxidase for the hydroxylation of phenol. Overall, the putative function of Orf13 as a tyrosine hydroxylase has been confirmed and establishes the first bacterial class of tyrosine hydroxylases.

Keywords

Anthramycin; lincomycin A; Orf13; LmbB2; tyrosine hydroxylase; heme peroxidase; heme b; pyrrolo[1,4]benzodiazepines; dihydroxyfumarate; ascorbate; aromatic hydroxylation

Pyrrolo[1,4]benzodiazepines (PBDs¹), lincosamides and hormaomycin are three classes of natural products from actinomycetes, which have antimicrobial and/or antitumor activities due to their different chemical properties (Fig. 1A). PBDs are sequence selective DNA alkylating compounds that inhibit transcription and replication processes (1), lincosamides

Corresponding Author: Barbara Gerratana, Department of Chemistry and Biochemistry, Bldg 091, University of Maryland, College Park, MD 20742, USA. Telephone: 1 (301) 405-3949; Fax: 1 (301) 314-9121; bgerrata@umd.edu.

Supporting Information Available: Additional supplementary figures and data including the multiple sequence analysis, purification gels, UV-visible and mass spectrometry spectra, kinetic data and substrate specificity results described in the manuscript text are available free of charge via the Internet at http://pubs.acs.org.

¹**Abbreviations:** Pyrrolo[1,4]benzodiazepine (PBD); inductively coupled plasma mass spectrometry (ICP-MS); high performance liquid chromatography fluorescence detection (HPLC-FLD); electron ionization spray mass spectrometry with tandem mass spectrometry (ESI-MS/MS); protoporphyrin IX (PPIX); δ-aminolevulinic acid (δ-ALA); dithiothreitol (DTT); superoxide dismutase (SOD); dihydroxyfumaric acid (DHFA); horseradish peroxidase (HRP).

disrupt and inhibit protein synthesis (2), and hormaomycin is a despipeptide with potent narrow-spectrum antibiotic activity (3). PBDs, lincosamides and hormaomycin share a common hydropyrrole moiety that originates from the same metabolic precursor, L-tyrosine (4-6). The tyrosine to hydropyrrole transformation is unique to the biosynthesis of these natural products and has remained largely uncharacterized. Putative assignment of the tyrosine hydroxylase and DOPA-dioxygenase activities proposed to be involved in the first two steps of this transformation is originally based on cell free extract studies of enzymes from the lincomycin A biosynthetic pathway (7) (Fig. 1B). Formation of the cyclized imine (4a) from L-tyrosine was observed using cell free extract from co-expression of the putative tyrosine hydroxylase (LmbB2) and DOPA-dioxygenase (LmbB1) (8, 9). LmbB1 alone converted L-DOPA to the same cyclic product (4a) suggesting that LmbB2 and its homologs Orf13, TomI, SibU and HrmE from the anthramycin, tomaymycin, sibiromycin and hormaomycin biosynthetic pathways (6, 10-12), respectively, are the putative tyrosine hydroxylase catalyzing the first step of this unprecedented transformation.

The chemical reaction of L-tyrosine to L-DOPA is an *ortho*-hydroxylation of an aromatic ring. Enzymes performing aromatic hydroxylation are recognized as monophenol monooxygenases and have been described in five different classes based on their cofactor requirement. These are the heme dependent cytochrome P450 enzymes and peroxidases (13), di-iron hydroxylases (14), non-heme iron pterin or α -ketoglutarate dependent monooxygenases (15), type III non-heme copper dependent monooxygenases (16) and the metal free flavin dependent monooxygenases (17). Within the five classes of monophenol monooxygenases, non-heme iron pterin or α -KG dependent enzymes have highly conserved 2-His-1-carboxylate triad catalytic motifs (18) and catalyze the ortho-hydroxylation of Ltyrosine to L-DOPA (15, 16). A BLAST search of the putative tyrosine hydroxylase homologs identifies only one other statistically significant protein, AMED_5527 from actinobacteria, which is also uncharacterized. The sequences of these six homologs do not contain any known conserved domains or conserved motifs (Fig. S1). This poses an intriguing question as to the cofactor requirement for this putative tyrosine hydroxylase. It may require an already established cofactor for monophenol monooxygenase activity, a new cofactor or have no cofactor requirement at all. In all cases, this enzyme likely represents a new class performing aromatic hydroxylation and oxidation reactions.

Presented here is the biochemical, biophysical and kinetic characterization of the putative tyrosine hydroxylase Orf13. These data confirm the functional assignment of these enzymes as tyrosine hydroxylases and establish their classification as heme dependent peroxidases. To the best of our knowledge this represents the first functional identification of a bacterial tyrosine hydroxylase, in addition to the first heme peroxidase that can utilize hydrogen peroxide for aromatic amino acid hydroxylation.

Experimental Procedures

Materials and Methods

All purification resins and protein molecular weight standards for the quaternary structure determination were purchased from G.E. Healthcare (Piscataway, NJ). The pET24a vector was purchased from Novagen (Darmstadt, Germany) and the pCW vector and RP523 *E. coli* strain were generously donated by Prof. Michael A. Marletta (UC-Berkeley). Fermentas (Glen Burnie, MD) mini-prep kit was used for DNA purification. Sodium phosphate, imidazole, sodium dithionite, and hydrogen peroxide (30% solution) were purchased with the highest purity from Thermo Fisher Scientific (Fair Lawn, NJ). Dithiothreitol (DTT) was purchased from American Bioanalytical Inc. (Natick, MA). Catalase, superoxide dismutase (SOD) and all other chemicals were purchased with the highest purity from Sigma Aldrich (St. Louis, MO). The Orf13 extinction coefficient was calculated by performing quantitative

amino acid analysis (AAA Service Laboratory; Damascus, Oregon) for triplicate samples with measured A₂₈₀ values. Metal analysis of Orf13 by inductively coupled plasma mass spectrometry (ICP-MS) was performed in Department of Geological Sciences at Michigan State University (East Lansing, MI). High performance liquid chromatography was performed with an Agilent 1000 Series HPLC (Foster City, CA) equipped with 1100 Series multiple wavelength and 1200 Series fluorescence detectors. All UV-visible absorption spectra or measurement of catechol-nitrite complexes for kinetic assays were obtained with a Varian UV-vis Cary100 Spectrophotometer with Temperature Controller (Walnut Creek, CA). Electron Ionization Spray Mass Spectrometry with tandem mass spectrometry (ESI-MS/MS) was performed with an LTQ Orbitrap XL (Thermo Scientific; San José, CA). Anaerobic experiments were performed in an 830-ABC series compact glovebox (PLAS-LABS, Inc; Lansing, MI) equipped with a Model 10 Gas Analyzer and Digital Heated Fan Box with palladium catalyst bed (Coy Laboratory Products, Inc; Grass Lake, MI).

Cloning of Native (non-fusion tagged) Orf13

The gene encoding Orf13 was amplified by PCR from the p-ANT-1 cosmid containing the anthramycin gene cluster constructed by Dr. Wei Li in our laboratory (unpublished results). NdeI and HindIII restriction sites were incorporated into the primers for insertion into the pET24a vector. Amplified *orf13* was digested with NdeI and HindIII, ligated into the pET24a vector and transformed into GeneHogs (Invitrogen; Carlsbad, CA). DNA sequencing confirmed correct construction of the pET24a/*orf13* plasmid for the recombinant expression of native Orf13 in BL21(DE3) *E. coli*. The *orf13* gene was also cloned into the pCW vector for recombinant expression in RP523 *E. coli* by digestion of pET24a/*orf13* with HindIII and NdeI and insertion into the pCW vector cut with the same restriction enzymes. DNA sequencing confirmed the correct construction of pCW/*orf13*.

Expression and Purification of Native Orf13 in BL21(DE3) E. coli

Orf13 was expressed in BL21(DE3) E. coli cells transformed with pET24/orf13. Cells were grown at 37 °C with 50 µg/mL kanamycin and induced with D-lactose (0.2% w/v) when the OD at 600 nm reached 0.8 – 1.0. Cells were harvested 8 hours after induction and the cell pellets were flash frozen in liquid nitrogen and stored at -80 °C until purification. Six grams of cells were lysed by French press and the cell free extract was loaded onto a 6 mL column of Ni-Sepharose pre-equilibrated with buffer A (50 mM sodium phosphate (pH 8.0), 300 mM NaCl and 1 mM DTT). The column was washed with 20 column volumes of buffer A containing 20 mM imidazole at 1 mL/min at 4 °C. Orf13 was eluted with 3 column volumes of buffer A containing 70 mM imidazole and fractions containing the enzyme were pooled and concentrated using a filtration membrane Amicon (30 kDa MWCO) by centrifugation (Millipore, Billerica, MA) to a concentration of 10 mg/mL. The concentrated enzyme solution was then loaded onto a S-200 HR column (2.5×40 cm; 196 mL column volume) pre-equilibrated with buffer B (10 mM imidazole, 50 mM sodium phosphate (pH 8.0), 300 mM NaCl and 10% glycerol) and eluted at 0.4 mL/min. Fractions containing Orf13 were pooled and concentrated to at least 10 mg/mL as previously described, flash frozen by liquid nitrogen in liquid droplets and stored at -80 °C. Purity of Orf13 was greater than 95% as judged by SDS-PAGE (Fig. S2A). The protein concentration was determined using the experimentally determined extinction coefficient ε_{280} 2.8 ± 0.2 mL mg⁻¹ cm⁻¹ (pH 8.0, 25 °C) with final purification yields of 2-3 mg of Orf13 per gram of cells lysed. An alternative purification method for Orf13 by anionic exchange chromatography was also developed. Six grams of cells were lysed by French press and the cell free extract was loaded onto a Q-Sepharose column (2.5×49 cm; 240 mL column volume) pre-equilibrated with buffer A (50 mM sodium phosphate (pH 8.0), 30 mM NaCl, 50 mM DTT and 10% glycerol). The column was washed with 3 column volumes of buffer A at 2 mL/min at 4 °C, followed by a salt gradient of 30 mM - 600 mM NaCl within 1.2 L. Orf13 eluted between 120 - 150 mM NaCl

of the linear gradient and fractions containing the enzyme were pooled and concentrated to 10 mg/mL as previously described. Gel filtration S-200HR chromatography was performed as described before with buffer containing 50 mM sodium phosphate (pH 8.0), 300 mM NaCl, 50 mM DTT and 10% glycerol. Orf13 was obtained with similar yield and purity as in the Ni-Sepharose method (Fig. S2B). For all reported specific activity and steady state kinetic data, Orf13 was purified and stored in buffer B (10 mM imidazole, 50 mM sodium phosphate (pH 8.0), 300 mM NaCl and 10% glycerol) to maintain stable enzyme with a ferric heme-iron oxidation state. Orf13 that had been purified and stored in the presence of 50 mM DTT was buffer exchanged into buffer B at 4 °C using a G-50 column (1 × 5 cm; 4 mL column volume) to remove DTT prior to enzyme assays. Auto-oxidation of the heme-iron to the ferric state upon buffer exchange was observed in the Soret band, which shifted from 420 nm to 405 nm (Fig S3).

Quaternary Structure Determination of Orf13 by Gel Filtration

The oligomeric state of purified Orf13 was determined using a Superdex200 column (1×30 cm; 24 mL column volume) pre-equilibrated at 4 °C with 50 mM sodium phosphate (pH 8.0), 150 mM NaCl and 50 mM DTT at 0.4 mL/min. Molecular weight standards used were ribonuclease A (13.7 kDa), ovalbumin (44 kDa), conalbumin (75 kDa) and aldolase (158 kDa).

High Performance Liquid Chromatography and Mass Spectrometry for Porphyrin Detection and Identification

An HPLC method to detect porphyrins was performed as previously described (19). Samples (110 μ L) of Orf13 and/or standards of heme b (iron protoporphyrin IX) or protoporphyrin IX (PPIX) were incubated at room temperature for 1 hour in 2% SDS (w/v). Porphyrins were detected at 405 nm. Heme b and PPIX standards had average retention times of 42 and 44 minutes, respectively. The peaks observed at 42 and 44 minutes from the Orf13 sample were collected, treated with formic acid (1% v/v,) and injected at 25 μ L/min into an ESI-MS. The parent ions of 616.3 m/z and 563.5 m/z observed for the 42 and 44 minute samples, respectively, were selected for fragmentation by Collision Induced Dissociation. Heme b and PPIX standards were treated and analyzed accordingly.

Heme b Quantitation and Stoichiometry

The pyridine hemochromagen method was performed as described (20) with a UV-vis Cary100 Spectrophotometer. A basic pyridine solution containing 50% (v/v) pyridine and 200 mM NaOH was prepared fresh for all analyses. The concentration of heme b from Orf13 samples is calculated with the extinction coefficient 22.1 mM⁻¹ cm⁻¹ for heme b and the stoichiometric ratio of heme b determined by the molar ratio of heme b to Orf13. All analyses were performed in triplicate.

Electron Paramagnetic Resonance of Orf13

Orf13 with 50% heme b occupancy purified and stored in the presence of 50 mM DTT was buffer exchanged into 20 mM sodium phosphate (pH 8.0) at 4 °C using a G-50 column (1 × 5 cm; 4 mL column volume). Auto-oxidation of heme b to the ferric state was observed after removal of DTT (refer to Fig S3), however 5 mM ferricyanide was also added to Orf13 to ensure complete oxidization of the heme-iron to the ferric state. The ferricyanide was removed by a second G-50 column (1 × 5 cm; 4 mL column volume) pre-equilibrated with 20 mM sodium phosphate (pH 8.0) at 4 °C. The final Orf13 sample was concentrated to 6 mg/mL, diluted 1:1 (v/v) in 100% glycerol (300 µL final volume), transferred to an EPR quartz tube and flash frozen slowly in liquid nitrogen. The sample was stored at -80 °C until EPR analysis. The EPR spectrum of Orf13 was obtained at The Johns Hopkins University in

the Department of Chemistry using a Bruker EMX EPR spectrometer controlled with a Bruker ER 041 X G microwave bridge at 15 K. The instrument was equipped with a continuous-flow liquid helium cryostat (ESR900) coupled to a temperature controller (TC503) made by Oxford Instruments, Inc.

Orf13 Activity Assays with Detection of L-Tyrosine and L-DOPA by HPLC-FLD

Orf13 (2.5 µM) was pre-incubated in 50 mM sodium phosphate (pH 8.0) containing 15 mM DTT or 15 mM dithionite for 5 minutes on ice and then incubated for 5 minutes at 37 °C before addition of L-tyrosine (1 mM final) to start the reaction. In assays testing the requirement of hydrogen peroxide, Orf13 was pre-incubated with L-tyrosine (1 mM final) for 5 minutes on ice, 5 minutes at 37 °C and then hydrogen peroxide (0.1 mM final) was added to initiate the reaction. All assays were performed at 37 °C up to 15 minutes in triplicate. Four time point aliquots (75 μ L) were quenched with 2.5 M HCl (10 μ L) and chloroform (40 µL) was added to the quenched samples, spun for 2 minutes at 3,400 rpm at room temperature. The aqueous layer (65 μ L) was transferred to new tube containing 2.5 M NaOH (10 µL). 20 µL from each sample were analyzed by HPLC-FLD as described for the detection of L-tyrosine and L-DOPA (21). L-Tyrosine and L-DOPA stocks were quantified spectrophotometrically at $\varepsilon_{275} = 1.4 \text{ mM}^{-1} \text{ cm}^{-1}$ (22) and $\varepsilon_{280} = 2.63 \text{ mM}^{-1} \text{ cm}^{-1}$ (23) respectively. L-DOPA and L-tyrosine standards had an average retention time of 4.5 and 5.5 minutes, respectively. The amount of L-DOPA produced by Orf13 was determined based on a calibration curve for L-DOPA made with standard samples quantified spectrophotometrically and treated under the same sample work up condition described. In Orf13 specific activity assays for the dihydroxyfumaric acid (DHFA) or L-ascorbate dependent reactions, Orf13 (2.5 µM) was pre-incubated with DHFA (2 mM) or L-ascorbate (25 mM) for 5 minutes on ice and then 5 minutes at 37 °C in 100 mM sodium phosphate (pH 8.0). The reaction was initiated by addition of L-tyrosine (5 mM) and carried out for 15 minutes with time point aliquots quenched, prepared and analyzed as described above. These assays were performed in triplicate with or without catalase (75 μ g/mL) or SOD (100 µg/ml), or were performed in an anaerobic glovebox. L-Ascorbate stocks were quantified spectrophotometrically at $\varepsilon_{290} = 2.8 \text{ mM}^{-1} \text{ cm}^{-1}$ (24).

L-DOPA Colorimetric Assay for the Steady State Kinetics of Orf13 of the Hydrogen Peroxide Dependent Reaction

A discontinuous assay was developed to monitor formation of L-DOPA in the hydrogen peroxide dependent reaction of Orf13 using a colorimetric method as previously described (25, 26). Orf13 (0.3 – 1 μ M; 75% heme b occupancy) was incubated with L-tyrosine for 5 minutes at 37 °C in 100 mM sodium phosphate (pH 8.0), followed by addition of hydrogen peroxide to initiate the reaction. Assays were performed in triplicate at 37 °C for 4 minutes with time points taken at 1, 2, 3, and 4 minutes in 90 µL aliquots quenched with 2.5 M HCl (10 µL). A solution containing 12.5% (w/v) sodium nitrite and 12.5% (w/v) sodium molybdate (35 μ L) was added to the quenched samples and incubated for 10 minutes at room temperature. NaOH (10 µL, 3 M) was added to the sample and the L-DOPA-nitrite complex was measured at 500 nm within 10-15 seconds. A standard curve of L-DOPA from 1 to 100 μ M was prepared the same day for each set of assays. L-tyrosine and L-DOPA stocks were quantified as previously described (22, 27). Hydrogen peroxide stocks were prepared fresh and quantified spectrophotometrically at $\varepsilon_{240nm} = 43.6 \text{ M}^{-1} \text{ cm}^{-1}$ (24). Fixed variable concentrations of L-tyrosine (125 µM to 5 mM) at a fixed concentration of hydrogen peroxide (500 μ M) were used to determine the steady state rate constants for L-tyrosine. Fixed variable concentrations of hydrogen peroxide (100 µM to 1 mM) at a fixed concentration of L-tyrosine (2 mM) were used to determine the steady state rate constants for hydrogen peroxide. The steady state data for both L-tyrosine and hydrogen peroxide were fit to the Michaelis-Menten equation using the software program Prism 4 (GraphPad) to obtain

the steady state rate constants. Assay controls with a blank solution without Orf13 were used to correct for background. Orf13 background control assays were carried out with the same concentration of enzyme in the absence of substrates. No enzyme background at 500 nm was observed with 1.5 μ M Orf13 or less. All controls were run in triplicate and in parallel with assay samples and underwent the same colorimetric workup described above.

Orf13 Specific Activity Assays with Substrate Analogues

Production of L-tyrosine was monitored by HPLC-FLD as described (21) for assays with Lphenylalanine as the substrate. Orf13 (1.5 µM) was incubated with L-phenylalanine (5 mM final) for 5 minutes at 37 °C in 100 mM sodium phosphate (pH 8.0) followed by addition of hydrogen peroxide (500 μ M final) to initiate the reaction. Assays were performed in triplicate at 37 °C for 4 minutes with time points taken at 1, 2, 3, and 4 minutes. Each time aliquot was treated as described for the HPLC-FLD method to detect the formation of Ltyrosine. Assay controls included the same concentrations as the activity assay sample; 1) Orf13 only, 2) Orf13 and L-phenylalanine, 3) L-phenylalanine, 4) L-phenylalanine with hydrogen peroxide, 5) L-tyrosine, and 6) 100 μ M L-tyrosine with hydrogen peroxide. All controls were run in triplicate the same day as the assay samples containing Orf13, Lphenylalanine and hydrogen peroxide, and underwent the same method workup described. Assays using the substrate analogues DL-*m*-tyrosine, tyramine, 3-(4-hydroxylphenyl) propanoic acid and p-cresol were monitored by the L-DOPA colorimetric assay for their respective catechol products; L-DOPA, dopamine, 3-(3,4-hydroxyphenyl) propanoic acid and 4-methylcatechol. Orf13 (1.5 μ M) was incubated with L-tyrosine (5 mM final) or substrate analogue (5 mM final) for 5 minutes at 37 °C in 100 mM sodium phosphate (pH 8.0), followed by addition of hydrogen peroxide (500 μ M final) to initiate the reaction. At 2 minutes, a time aliquot from each substrate analogue reaction was taken, underwent the same colorimetric workup as described and were scanned using a Varian UV-vis Cary100 Spectrophotometer for the formation of the catechol-nitrite complex. For assays assessing the relative specific activity for substrate selectivity, Orf13 (1.5 μ M) was incubated with Ltyrosine (5 mM final) or substrate analogue (5 mM final) for 5 minutes at room temperature in 100 mM sodium phosphate (pH 8.0), followed by addition of hydrogen peroxide (250 µM final) to initiate the reaction. Assays were performed in triplicate with each substrate at room temperature for 11 minutes with time aliquots taken at 1, 3, 6, and 11 minutes. Standard curves of the respective catechol products from 1 to 100 μ M were prepared the same day for each set of assays. These substrate analogues and catechol products were quantified spectrophotometrically at $\varepsilon_{275nm} = 1.4 \text{ mM}^{-1} \text{ cm}^{-1}$ and $\varepsilon_{280nm} = 2.63 \text{ mM}^{-1} \text{ cm}^{-1}$, respectively. Assay controls with a blank solution without Orf13 were used to correct for background. Orf13 background control assays were carried out with the same concentration of enzyme in the absence of substrates. No enzyme background at 500 nm was observed with 1.5 μ M Orf13 or less. All controls were run in triplicate and in parallel with assay samples and underwent the same colorimetric workup described above.

Results and Discussion

Expression and Purification of Native Orf13 in BL21(DE3) E. coli

Cell pellets after over expression of Orf13 are red in color and the color of the expression media becomes dark brown or black when expression is continued for more than 8 hours. The red cell color was the first indication of a cofactor likely bound to Orf13, while production of the black pigment suggested the enzyme to be active since this has been observed for the oxidative polymerization of L-DOPA (28). Non-fusion tagged Orf13 showed affinity for Ni-Sepharose resin and was utilized for purification. Auto-oxidative degradation of Orf13 observed by SDS-PAGE (Fig. S2C) by the appearance of a band of MW consistent with a covalent dimer correlated with a distinct color change of the enzyme

from dark red to brownish-yellow and occurred at purification steps that did not contain excess DTT (50 mM) or ascorbate (25 mM), or had removed imidazole from the buffer during gel filtration. The formation of an apparent covalent dimer and spectral changes of the heme seem to indicate that oxidative damage occurs both at an amino acid residue and at the heme. Protection of Orf13 by including either DTT (50 mM), ascorbate (25 mM) or imidazole (10 mM) during gel filtration is achieved by reduction of the heme or by scavenging radicals. Pure and stable Orf13 exists as a monomer in solution with an experimentally observed molecular weight of 37.9 kDa consistent with the predicted monomeric weight of 33.6 kDa.

Heme b is bound to Orf13

Characteristic absorbance bands of a heme moiety were observed in a UV-visible absorption spectrum of purified Orf13 (Fig. 2). The Soret band at 408 nm indicated a ferric heme-iron in a penta-coordinate state based on the presence of a Q-band at 630 nm. Heme b was identified as the heme moiety non-covalently bound to Orf13 by co-elution with standard heme b by HPLC (Fig. 3). The HPLC peak at 42 minutes from the supernatant of denatured Orf13 was confirmed as heme b with subsequent ESI-MS/MS analysis (Fig. S4). No other organic cofactors were identified with Orf13 and no other metals, other than iron originating from heme b, were found by ICP-MS. This information excludes classification of Orf13 as any of the non-heme dependent monophenol monooxygenases previously mentioned, in particular, the non-heme iron pterin or alpha-KG dependent enzymes and the copper dependent tyrosinases that catalyze the *ortho*-hydroxylation of L-tyrosine to L-DOPA (15, 16).

Stoichiometry of Heme b in Orf13

A wide range of heme b occupancy from 10% to 100% was observed with Orf13 purified under conditions protecting the enzyme from degradation. Orf13 with 100% heme b occupancy has a RZ value of 1.8 based on the ratio of the heme absorbance at 408 nm to protein absorbance at 280 nm (Note: 100% heme b occupancy is defined as 1 heme b moiety per monomer of enzyme). We determined that Orf13 is also occupied by PPIX and the amount of PPIX bound to Orf13 made up the occupancy difference when sub-stoichiometric amounts of heme b were measured in purified enzyme (i.e. 75% heme b and 25% PPIX). The presence of a second porphyrin species bound to Orf13 other than heme b was evident by the appearance of two distinct Soret band species at 406 nm and 431 nm in dithionite reduced enzyme (Fig. S5). The Soret band species at 406 nm is PPIX, which remains unaffected by dithionite as it lacks an iron center. The presence of PPIX bound to Orf13 was further confirmed after co-injection of PPIX with Orf13 showed an increase of the peak observed at 44 minutes (co-injection data not shown, refer to Figure 3) and subsequent ESI-MS/MS analysis (Fig. S6). The amount of PPIX bound to Orf13 was determined by a calibration curve using HPLC and spectrophotometrically quantified PPIX ($\varepsilon_{408nm} = 262$ mM⁻¹ cm⁻¹ in 2.7 M HCl (29)) from which the stoichiometry was calculated by the molar ratio of PPIX and Orf13. This is the first reported case where a heme containing enzyme has been found to be fully occupied with a heterogeneous mixture of heme b and PPIX. Dissociation constants of heme b for enzymes utilizing the heme moiety in different capacities show a range in heme binding affinities; myoglobin for oxygen transport $(1.3 \times$ 10^{-14} M) (30), bovine serum albumin for transport (4.6 × 10⁻⁹ M) (31), pa-HO, a heme oxygenase, for heme degradation $(0.6 \times 10^{-6} \text{ M})$ and PhuS involved in heme binding, trafficking and transfer $(0.2 \times 10^{-6} \text{ M})$ (32). The dissociation constant of PPIX for ferrochelatase (1.5×10^{-6} M) (33) has similar binding affinity as *pa*-HO and PhuS have for heme b. Heme b and PPIX are tightly bound to Orf13 as there is no exchange or loss during dialysis unless the enzyme is denatured with 6 M guanidinium hydrochloride or 2% SDS to remove either species. The occupancy ranges of heme b and PPIX with Orf13 may indicate

this enzyme to have similar binding affinities for both porphyrin moieties. The lack of *in vivo* binding discrimination between heme b and PPIX may also suggest stronger binding interactions with protein residues and substituents of porphyrin ring (i.e. the propanoic acid or vinyl groups) than the axial residues coordinating the heme-iron.

The extensive variability in heme b occupancy for Orf13 was observed in expression batches from the same seed culture, prepared in the same liquid media, and grown and expressed on the same shaker using identical flasks. Heme dependent enzymes obtained from E. coli expression systems that require a non-covalently bound heme are predominantly an apo form with partial heme occupancy without the presence of PPIX (34-36). Complete heme occupancy can be readily achieved by addition of heme to the enzyme by titration without the need for protein denaturation and refolding. In vitro titration of heme b to purified Orf13 did not exchange the bound PPIX and the enzyme remained fully occupied with a heterogeneous mixture of both porphyrin species. Attempts to obtain an apo form of Orf13 for in vitro heme titration was also unsuccessful since the enzyme failed to express when 1,10-phenanthroline, a metal chelating agent, was added to the growth medium. In an effort to increase and control the *in vivo* incorporation of heme b in Orf13, δ -aminolevulinic acid (δ -ALA, a heme biosynthetic precursor (37)), exogenous non-heme iron with or without δ -ALA, or exogenous hemin were added to the medium for expression in BL21(DE3) E. coli. This strategy was ineffective as similar results in heme b occupancy (30-100%) were observed compared to Orf13 expression without any additives. It was also determined that the range in heme b and PPIX occupancies with Orf13 is independent of the purification method. Purification of Orf13 by anionic exchange (Q-Sepharose) in the presence of excess DTT (50 mM) to protect Orf13 from auto-oxidative degradation showed the same variable heme b occupancies as the metal affinity method (Ni-Sepharose). This confirmed that heme b bound to Orf13 was not compromised, lost or competed out due to the enzyme's ability to intrinsically bind to Ni-Sepharose.

An alternative E. coli expression system for in vivo incorporation of heme b in Orf13 was tried using RP523 E. coli with exogenous hemin. RP523 is a porphyrin permeable strain of E. coli with a mutation in the *hemB* gene of the heme biosynthetic pathway that disrupts the normal biosynthesis of heme b causing the cells to be dependent on the uptake of exogenous heme b for survival (38). This expression system has been established for substituting nitric oxide synthase (NOX), a heme dependent enzyme, with different metalloporphyrins (19, 39). The advantage in utilizing this system for Orf13 expression is that these cells lack the ability to synthesize porphyrin and are only viable in the presence of heme b, thus eliminating the presence of PPIX with Orf13. RP523 E. coli cells expressing Orf13 using the pCW/orf13 construct were red in color as observed with Orf13 expression in BL21(DE3) E. coli. However, it was difficult to obtain stable Orf13 using the developed purification methods previously described. Severe degradation of Orf13 was evident with the Ni-Sepharose method in the presence of imidazole. Orf13 eluted as a brownish-yellow enzyme and showed auto-oxidative degradation by SDS-PAGE with a predominant protein band at double the monomeric weight of Orf13 as previously observed in purifications of Orf13 from BL21(DE3) E. coli without oxidative protection (Fig. S2C). Repeating the Ni-Sepharose purification under anaerobic conditions in a glove box prevented dimerization of Orf13 and the enzyme retained its red color. The visible absorption spectrum of heme b bound to Orf13 was similar to Orf13 purified from BL21(DE3) E. coli (refer to Fig. 2). However, the overall yield and purity were very poor. Purification by the Q-Sepharose method with excess DTT (50 mM) prevented covalent dimerization and improved the purity of the protein sample. However, Orf13 eluted as a bright yellow enzyme with an unusual visible absorption spectrum of the heme displaying a broad Soret band at 420 nm without distinguishable Q-bands. In addition, the heme species bound to Orf13 could not be reduced by dithionite to assess its heme b stoichiometry by the pyridine hemochromagen method.

Overall, the feasibility in obtaining sufficient amounts of highly pure and stable Orf13 fully occupied with heme b from RP523 *E. coli* was unsuccessful and proved more challenging than the purification of Orf13 expressed in BL21(DE3) *E. coli*.

Catalytic Assessment of Heme b for L-Tyrosine Hydroxylation

Orf13 was not expected to be a heme dependent cytochrome 450-like enzyme since there are no conserved cysteine or methionine residues (Fig. S1). This was confirmed when DTT or dithionite reduced Orf13 in the presence of L-tyrosine did not produce L-DOPA. Production of L-DOPA was observed when hydrogen peroxide was added to Orf13 in the presence of Ltyrosine (Fig. S7). This implicated the catalytic requirement of heme b. A modified discontinuous assay for spectrophotometric detection of L-DOPA in a L-DOPA-nitrite colorimetric complex (25, 26) was utilized to measure the specific activity and steady state kinetics of Orf13 (Table 1) due to the limited sensitivity of the HPLC-FLD analysis. The specific activity of Orf13 for the hydrogen peroxide dependent reaction correlated with the stoichiometry of heme b where maximal turnover of ferric-heme Orf13 (100% heme b) was $32 \pm 2 \text{ min}^{-1}$ compared to $21 \pm 1 \text{ min}^{-1}$ with ferric-heme Orf13 (48% heme b). The specific activity was also dependent on the heme-iron oxidation state where ferric-heme Orf13 (48% heme b) had greater catalytic activity $(21 \pm 1 \text{ min}^{-1})$ than Orf13 with ferrous-heme in the presence of 50 mM DTT (9 \pm 1 min⁻¹). This is in agreement with a catalytic starting state of ferric heme-iron for heme peroxidases (40). These results established heme b as the cofactor required for catalysis, classifying Orf13 as a heme dependent peroxidase catalyzing the ortho-hydroxylation of L-tyrosine to L-DOPA. The steady state rate constants for L-tyrosine and hydrogen peroxide were determined using the L-DOPA colorimetric assay and the preincubation condition of Orf13 with L-tyrosine prior to reaction initiation by addition of hydrogen peroxide (Table 1; Fig. S8 for Michaelis Menten curves). The steady state kinetic parameters for L-tyrosine hydroxylation by Orf13 fit to the Michaelis-Menten model are within the range of values reported for other heme peroxidases (41) and the catalytic efficiency for both substrates is similar.

Tyrosine hydroxylation to L-DOPA by Orf13 is also observed in the presence of L-ascorbate or DHFA (Fig. S9). The ascorbate and DHFA dependent reactions require molecular oxygen and have similar k_{obs} that are 48 and 58 fold less than the k_{obs} of the hydrogen peroxide dependent reaction, respectively (Table 2). Aromatic hydroxylation by the DHFA dependent reaction was abolished in the presence of SOD and was not observed with catalase, while the ascorbate dependent reaction was not affected by SOD and decreased 4 fold in the presence of catalase. Interestingly, hydroxylation of phenols has been reported for horseradish peroxidase (HRP) in the presence of DHFA as an oxygen transfer reaction similar to cytochrome P450 enzymes (42, 43). The peroxygenase activity of HRP is promoted by non-enzymatic production of superoxide by DHFA and molecular oxygen, which then causes the formation of Compound III, an oxyferrous heme-iron state, when superoxide binds to the heme. Hydroxylation of phenol only occurs when substrate and additional reducing equivalents of DHFA are present with HRP-Compound III (42). Hydroxylation of L-tyrosine to L-DOPA by Orf13 in the presence of DHFA is in agreement with the HRP peroxygenase activity for aromatic hydroxylation. Although molecular oxygen dependent hydroxylation of L-tyrosine by Orf13 in the presence of ascorbate or DHFA is observed, it does not appear to be the primary catalytic pathway for L-tyrosine hydroxylation since turnover is enhanced 48 and 58 fold, respectively, when hydrogen peroxide is provided as a substrate for the hydroxylation reaction even in the absence of molecular oxygen under anaerobic conditions (Table 2).

HRP and other heme peroxidases such as myeloperoxidase and chloroperoxidase are known to catalyze dimerization of aromatic substrates in the presence of hydrogen peroxide by way of the classical two sequential one-electron transfer mechanism (27, 44, 45). However,

hydroxylation of aromatic amino acids in the presence of hydrogen peroxide by heme peroxidases has not been reported (42). These results emphasize the novelty of Orf13 for its ability to use hydrogen peroxide for aromatic hydroxylation of L-tyrosine. A possible mechanism for this reaction may share the initial steps of the classic heme peroxidase catalytic cycle up to the formation of Compound I (Scheme 1) (27, 44, 45). Compound I is also an intermediate in the hydroxylation reactions catalyzed by P450 enzymes for the oxygen dependent reaction and the peroxide shunt pathway (17, 46). It has also been proposed in the hydrogen peroxide dependent hydroxylation reactions of heme-thiolate peroxygenases (17, 47). As these peroxygenases represent heme-thiolate enzymes functioning more like heme peroxidases in their substrate specificity for hydrogen peroxide (17, 47), Orf13 may represent the first heme-histidyl enzyme and mechanistic bridge between the heme peroxidases and the P450 enzymes. Therefore, subsequent steps after formation of Compound I may be reminiscent of the electron rebound mechanism proposed by Groves for P450 enzymes (Scheme 1) (46, 48). Formation of the product complex with the oxygen coordinated to the iron(III) center may proceed through a hydroxyl iron(IV) substrate radical complex obtained by hydrogen abstraction by Compound I from the substrate (48). Alternatively, this substrate radical could react with a second substrate radical similarly produced to yield the dimeric product characteristic of peroxidase reactions (27, 40). The fate of the reaction either toward hydroxylation or dimerization depends on the reactivity of the Compound I complex, which is controlled by steric and electronic interactions in the active site (49, 50). These interactions may significantly reduce the life time of this radical intermediate preventing dimerization and/or may stabilize the hydroxylation transition state.

Sequence Analysis of Orf13 as a Heme Peroxidase

Spectroscopic data supporting Orf13 as a heme peroxidase is evident by a Soret band position at 421 nm in a reduced-CO spectrum of Orf13 (Fig. 4A), and a low temperature electron paramagnetic resonance spectrum of ferric-heme Orf13 showing a predominant high spin heme iron with a g-value centered at 5.8 (Fig. 4B). This spectroscopic data with the comparative analysis of the highly conserved residues in Orf13 (Fig. S1) to other heme peroxidases suggests a histidyl-ligated heme-iron. However, Orf13 and its homologs were not initially identified as heme dependent peroxidases by BLAST (blastp) analysis nor by the PeroxiBase database (51) (http://peroxidase.isb-sib.ch/). Reassessment of the conserved residues in the multiple sequence alignment of Orf13 and homologs reveals some similarity to the conserved distal site motif RX₂F(W)H characteristic of Class I, II and III peroxidases represented by ascorbate peroxidase, Arthromyces ramosus peroxidase and HRP, respectively. These heme peroxidases have a proximal histidine residue coordinating the heme-iron as the fifth ligand between 120 to 138 residues away from the conserved distal histidine (52-55). In Orf13, a highly conserved region containing $R^{71}W^{72}X_3H^{76}$ has the same conserved residues as the distal site RX₂F(W)H motif of Class I, II and III peroxidases. The similarity in these motifs between unrelated enzymes suggests the evolutionary adaptation for the utilization of hydrogen peroxide for oxidative reaction by heme dependent enzymes. However, residue spacing is different between W72 and H76 than the R and F/W, and the two highly conserved histidine residues (H140 and H184), one of which may act as the proximal heme-iron ligand, are closer in sequence to H76 of the potential distal site by 63 and 107 residues, respectively. These differences in sequence spacing within the potential distal site motif and the proximal histidine may explain why Orf13 was not recognized as a heme peroxidase and might be required for the different reactivity of Orf13 compared to Class I, II and III peroxidases, revealing the existence of a new class of bacterial heme peroxidases.

Evaluation of Substrate Order for Catalysis and Inactivation by Hydrogen Peroxide

Heme peroxidases typically bind hydrogen peroxide first, although the heme-iron can become trapped in a nonproductive oxyferrous state (Compound III) during the catalytic cycle (40). Characteristic bands for Compound III in HRP include a Soret band at 417 nm and Q-bands at 544 nm and 580 nm (56). For Orf13, reversed substrate order of addition is necessary for catalysis with pre-incubation with L-tyrosine prior to the addition of hydrogen peroxide (Fig. S10). No turnover is observed if hydrogen peroxide is incubated with Orf13 before the addition of L-tyrosine. UV-visible absorption scans of Orf13 were taken before and after addition of hydrogen peroxide in the absence of L-tyrosine to investigate whether the lack of catalysis by the hydrogen peroxide Orf13 complex is due to formation of Compound III (Fig. 5A). The spectrum measured in the presence of hydrogen peroxide shows a significant decrease in the Soret band intensity and disappearance of the Q bands at 503 nm and 630 nm that is unlike the characteristic spectrum of HRP-Compound III. However, the formation of Compound III may be transient for Orf13 even though this hemeiron state has been shown to be stable in HRP for at least five minutes (56). This may suggest a different hydrogen peroxide inactivation mechanism for Orf13.

No changes in the heme spectrum were observed by addition of L-tyrosine to Orf13. This may indicate that the role of L-tyrosine as the first substrate added is simply to protect Orf13 from hydrogen peroxide inactivation and does not affect the coordination of the heme-iron as shown by the retention of the 630 nm Q-band (Fig. 5B). Interaction of L-tyrosine at the heme edge is consistent as there are no changes in the heme spectrum and is evident in heme spectra during catalysis after the addition of hydrogen peroxide to Orf13 pre-incubated with L-tyrosine (Fig. 5B). During catalysis the absorbance intensity from 450 nm to 600 nm, most notable in the Q-band at 503 nm, increased over time up to 6 minutes, after which no more changes were observed. The pattern of absorbance change at 503 nm is similar to what is observed for L-DOPA production by the colorimetric assay when Orf13 is pre-incubated with L-tyrosine and the reaction initiated with hydrogen peroxide (Fig. S10). The increase in the 503 nm Q-band is similar to a dehaloperoxidase bound complex with 2,4-dichloroquinone product (57) and could therefore be attributed to an Orf13 bound complex with L-DOPA.

Substrate Specificity for the Hydrogen Peroxide Dependent Aromatic Hydroxylation Reaction by Orf13

Heme peroxidases are promiscuous enzymes capable of oxidizing a wide assortment of aromatic substrates. Their lack of substrate specificity has been attributed to a larger active site that can accommodate various substrates, as well as the presence of additional substrate binding locations in the vicinity of the exposed heme edges where the reaction can also occur (58). The substrate analogues L-phenylalanine, DL-*m*-tyrosine, tyramine, 3-(4hydroxyphenyl) propanoic acid and p-cresol were selected to test the substrate specificity of Orf13 (Fig. S11), as well as to evaluate the requirement of chemical substituents on the aromatic ring in order for the hydroxylation reaction to occur. The para-substituted phenols (tyramine, 3-(4-hydroxyphenyl) propanoic acid and *p*-cresol) were converted by Orf13 in the presence of hydrogen peroxide to their respective catechol products, which were detected as colorimetric catechol-nitrite complexes using the L-DOPA colorimetric assay (Fig. S12). Comparison of the relative specific activity of these substrate analogues to Ltyrosine was unsuccessful as formation of the product analogues plateaued after the first minute of turnover, while L-DOPA formation from L-tyrosine remained linear up to 6 minutes (Fig. \$13). Orf13 is more susceptible to inactivation by hydrogen peroxide in the presence of these substrate analogues than with L-tyrosine. No increase in catechol product formation was detected when L-tyrosine was added to the p-cresol reaction after 1 minute, confirming the inactivation of Orf13 (data not shown). No L-phenylalanine conversion to L-

tyrosine was observed using an HPLC-FLD method to detect L-tyrosine, and no L-DOPA formation was observed using the L-DOPA colorimetric assay when DL-*m*-tyrosine was provided as a substrate. These results show that the hydroxyl group at the *para* position of the aromatic ring is necessary for hydroxylation since conversion of L-tyrosine, tyramine, 3-(4-hydroxyphenyl) propanoic acid and *p*-cresol to their respective catechol products is observed. Moreover, *ortho*-hydroxylation by Orf13 seems to be specific for L-tyrosine as the only substrate that protects from hydrogen peroxide inactivation.

In conclusion, we have successfully purified and confirmed the putative function of Orf13 from the anthramycin biosynthetic pathway as a tyrosine hydroxylase. The sequence of Orf13 is not similar to any known characterized proteins, nor does it contain conserved domains or motifs characteristic of enzymes performing hydroxylation reactions. We have provided spectroscopic and kinetic evidence that classifies Orf13 as a heme dependent peroxidase. Similar to heme-histidyl peroxidases, Orf13 displays a secondary hydroxylation activity of aromatic substrates in the presence of molecular oxygen and L-ascorbate or DHFA. However, unlike these heme peroxidases this enzyme catalyzes hydrogen peroxide dependent *ortho*-hydroxylation instead of dimerization by radical coupling, and the substrate order of addition is reversed with a required pre-incubation with L-tyrosine for activity. Orf13 can hydroxylate other *para*-substituted phenols but is inactivated by hydrogen peroxide much more readily than when L-tyrosine is the substrate. This implicates a catalytic mechanism requiring the *para*-phenol substituent for hydroxylation as no turnover for Lphenylalanine or DL-*m*-tyrosine was observed, as well as demonstrates Orf13 to have substrate selectivity for L-tyrosine. Therefore, we propose that Orf13 represents a new class of heme-histidyl ligated hydrogen peroxide dependent hydroxylases. In addition, Orf13 is the first identified heme peroxidase specific for L-tyrosine and is the first identified bacterial tyrosine hydroxylase.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Dr. Charles Long, Dr. Amanda J. McGown and Dr. David P. Goldberg for their assistance with the low temperature EPR experiment; Dr. Michael A. Marletta for the generous gifts of the pCW vector and RP523 *E. coli* strain; Dr. Zvi Kelman for use of the Superdex200 gel filtration system to determine the quaternary structure of Orf13 in solution; and Dr. Steven E. Rokita for helpful discussions.

This work was supported by NIH Grant GM084473 (B.G).

References

- 1. Gerratana B. Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines. Med Res Rev. 2011; 31 n/a. 10.1002/med.20212
- Spízek J, Rezanka T. Lincomycin, clindamycin and their applications. Appl Microbiol Biotechnol. 2004; 64:455–464. [PubMed: 14762701]
- 3. Rössner E, Zeeck A, König WA. Elucidation of the Structure of Hormaomycin. Angew Chem Intl Edit. 1990; 29:64–65.
- Hurley LH, Lasswell WL, Ostrander JM, Parry R. Pyrrolo[1,4]benzodiazepine antibiotics. Biosynthetic conversion of tyrosine to the C2- and C3-proline moieties of anthramycin, tomaymycin, and sibiromycin. Biochem. 1979; 18:4230–4237. [PubMed: 582801]
- Brahme NM, Gonzalez JE, Rolls JP, Hessler EJ, Mizsak S, Hurley LH. Biosynthesis of the lincomycins. 1. Studies using stable isotopes on the biosynthesis of the propyl- and ethyl-L-hygric acid moieties of lincomycins A and B. J Am Chem Soc. 1984; 106:7873–7878.

- Höfer I, Crüsemann M, Radzom M, Geers B, Flachshaar D, Cai X, Zeeck A, Piel J. Insights into the Biosynthesis of Hormaomycin, An Exceptionally Complex Bacterial Signaling Metabolite. Chem Biol. 2011; 18:381–391. [PubMed: 21439483]
- Peschke U, Schmidt H, Zhang HZ, Piepersberg W. Molecular characterization of the lincomycinproduction gene cluster of *Streptomyces lincolnensis* 78-11. Mol Microbiol. 1995; 16:1137–1156. [PubMed: 8577249]
- Novotna J, Honzatko A, Bednar P, Kopecky J, Janata J, Spizek J. I-3,4-Dihydroxyphenyl alanineextradiol cleavage is followed by intramolecular cyclization in lincomycin biosynthesis. Eur J Biochem. 2004; 271:3678–3683. [PubMed: 15355345]
- 9. Neusser D, Schmidt H, Spizek J, Novotna J, Peschke U, Kaschabeck S, Tichy P, Piepersberg W. The genes lmbB1 and lmbB2 of *Streptomyces lincolnensis* encode enzymes involved in the conversion of l-tyrosine to propylproline during the biosynthesis of the antibiotic lincomycin A. Arch Microbiol. 1998; 169:322–332. [PubMed: 9531633]
- Hu Y, Phelan V, Ntai I, Farnet CM, Zazopoulos E, Bachmann BO. Benzodiazepine Biosynthesis. Streptomyces refuineus Chem Biol. 2007; 14:691–701.
- Li W, Chou S, Khullar A, Gerratana B. Cloning and Characterization of the Biosynthetic Gene Cluster of Tomaymycin, an SJG-136 monomeric analog. Appl Environ Microbiol. 2009; 75:2958– 2963. [PubMed: 19270147]
- Li W, Khullar A, Chou S, Sacramo A, Gerratana B. Biosynthesis of Sibiromycin, a potent antitumor antibiotic. Appl Environ Microbiol. 2009; 75:2869–2878. [PubMed: 19270142]
- Sono M, Roach MP, Coulter ED, Dawson JH. Heme-Containing Oxygenases. Chem Rev. 1996; 96:2841–2888. [PubMed: 11848843]
- Leahy JG, Batchelor PJ, Morcomb SM. Evolution of the soluble diiron monooxygenases. FEMS Microbiol Rev. 2003; 27:449–479. [PubMed: 14550940]
- Fitzpatrick PF. Mechanism of Aromatic Amino Acid Hydroxylation. Biochem. 2003; 42:14083– 14091. [PubMed: 14640675]
- Rosenzweig AC, Sazinsky MH. Structural insights into dioxygen-activating copper enzymes. Curr Opin Struct Biol. 2006; 16:729. [PubMed: 17011183]
- Ullrich R, Hofrichter M. Enzymatic hydroxylation of aromatic compounds. Cell Mol Life Sci. 2007; 64:271. [PubMed: 17221166]
- Koehntop KD, Emerson JP, Que L. The 2-His-1-carboxylate facial triad: a versatile platform for dioxygen activation by mononuclear non-heme iron(II) enzymes. J Biol Inorg Chem. 2005; 10:87– 93. [PubMed: 15739104]
- Woodward JJ, Martin NI, Marletta MA. An *Escherichia coli* expression-based method for heme substitution. Nat Methods. 2007; 4:43–45. [PubMed: 17187078]
- 20. Berry EA, Trumpower BL. Simultaneous determination of hemes *a*, *b*, and *c* from pyridine hemochrome spectra. Anal Biochem. 1987; 161:1–15. [PubMed: 3578775]
- Olsovská J, Novotná J, Flieger M, Spízek J. Assay of tyrosine hydroxylase based on highperformance liquid chromatography separation and quantification of L-dopa and L-tyrosine. Biomed Chromatogr. 2007; 21:1252–1258. [PubMed: 17604359]
- 22. Edelhoch H. The Properties of Thyroglobulin. J Biol Chem. 1962; 237:2778-2787.
- 23. The Merck Index. 13th. Entry# 5485
- Hiner AN, Rodriguez-Lopez JN, Arnao MB, Lloyd Raven E, Garcia-Canovas F, Acosta M. Kinetic study of the inactivation of ascorbate peroxidase by hydrogen peroxide. Biochem J. 2000; 348:321–328. [PubMed: 10816425]
- 25. Arnow LE. Colormetric Determination of the Components of 3,4-dihydroxyphenylalanine-tyrosine Mixtures. J Biol Chem. 1937; 118:531–537.
- Fitzpatrick PF. Steady-state kinetic mechanism of rat tyrosine hydroxylase. Biochem. 1991; 30:3658–3662. [PubMed: 1673058]
- Marquez LA, Dunford HB. Kinetics of Oxidation of Tyrosine and Dityrosine by Myeloperoxidase Compounds I and II. J Biol Chem. 1995; 270:30434–30440. [PubMed: 8530471]
- Morris F. Non-Enzymatic Oxidation of Tyrosine and Dopa. Proc Natl Acad Sci U S A. 1950; 36:606–611. [PubMed: 14808146]

- 29. Falk, JE. Porphyrins and metalloporphyrins. Elsevier; Amsterdam: 1964. p. 236
- Hargrove MS, Barrick D, Olson JS. The Association Rate Constant for Heme Binding to Globin Is Independent of Protein Structure. Biochem. 1996; 35:11293–11299. [PubMed: 8784183]
- Gattoni M, Boffi A, Sarti P, Chiancone E. Stability of the heme-globin linkage in ab dimers and isolated chains of human hemoglobin. A study of the heme transfer reaction from the immobilized proteins to albumin. J Biol Chem. 1996; 271:10130–10136. [PubMed: 8626572]
- Bhakta MN, Wilks A. The Mechanism of Heme Transfer from the Cytoplasmic Heme Binding Protein PhuS to the δ-Regioselective Heme Oxygenase of. Pseudomonas aeruginosa Biochem. 2006; 45:11642–11649.
- Dailey HA. Spectroscopic examination of the active site of bovine ferrochelatase. Biochem. 1985; 24:1287–1291. [PubMed: 3986176]
- 34. Mulrooney SB, Waskell L. High-Level Expression in *Escherichia coli* and Purification of the Membrane-Bound Form of Cytochrome b5. Prot Expr Pur. 2000; 19:173–178.
- Suits MDL, Jaffer N, Jia Z. Structure of the *Escherichia coli* O157:H7 Heme Oxygenase ChuS in Complex with Heme and Enzymatic Inactivation by Mutation of the Heme Coordinating Residue His-193. J Biol Chem. 2006; 281:36776–36782. [PubMed: 17023414]
- Dalton DA, del Castillo LD, Kahn ML, Joyner SL, Chatfield JM. Heterologous Expression and Characterization of Soybean Cytosolic Ascorbate Peroxidase. Arch Biochem Biophys. 1996; 328:1–8. [PubMed: 8638916]
- Kimoto H, Matsuyama H, Yumoto I, Yoshimune K. Heme content of recombinant catalase from *Psychrobacter* sp. T-3 altered by host *Escherichia coli* cell growth conditions. Prot Expr Pur. 2008; 59:357–359.
- Li JM, Umanoff H, Proenca R, Russell CS, Cosloy SD. Cloning of the *Escherichia coli* K-12 *hemB* gene. J Bacteriol. 1988; 170:1021–1025. [PubMed: 3276659]
- Winter MB, McLaurin EJ, Reece SY, Olea C, Nocera DG, Marletta MA. Ru-Porphyrin Protein Scaffolds for Sensing O2. J Am Chem Soc. 2010; 132:5582–5583. [PubMed: 20373741]
- 40. Ortiz de Montellano, PR. Catalytic Mechanisms of Heme Peroxidases. In: Torres, E.; Ayala, M., editors. Biocatalysis Based on Heme Peroxidases. Springer-Verlab; Berlin Heidelberg: 2010.
- Garcia-Arellano, H. A Compendium of Bio-Physical-Chemical Properties of Peroxidases. In: Torres, E.; Ayala, M., editors. Biocatalysis Based on Heme Peroxidases. Springer-Verlab; Berlin Heidelberg: 2010.
- Dordick JS, Klibanov AM, Marletta MA. Horseradish Peroxidase Catalyzed Hydroxylations: Mechanistic Studies. Biochem. 1986; 25:2946–2951. [PubMed: 3718931]
- Halliwell B. Generation of Hydogen Peroxide, Superoxide, and Hydroxyl Radicals during the Oxidation of Dihydroxyfumaric acid by Peroxidase. Biochem J. 1977; 163:441–448. [PubMed: 195574]
- 44. Casella L, Gullotti M, Selvaggini C, Poli S, Beringhelli T, Marchesini A. The Chloroperoxidase-Catalyzed Oxidation of Phenols. Mechanism, Selectivity, and Characterization of Enzyme-Substrate Complexes. Biochem. 1994; 33:6377–6386. [PubMed: 8204570]
- Heinecke JW, Li W, Daehnke HL, Goldstein JA. Dityrosine, a specific marker of oxidation, is synthesized by the myeloperoxidase-hydrogen peroxide system of human neutrophils and macrophages. J Biol Chem. 1993; 268:4069–4077. [PubMed: 8382689]
- 46. Rittle J, Green MT. Cytochrome P450 Compound I: Capture, Characterization, and C-H Bond Activation Kinetics. Science. 2010; 330:933–937. [PubMed: 21071661]
- Matsunaga I, Sumimoto T, Ayata M, Ogura H. Functional modulation of a peroxygenase cytochrome P450: novel insight into the mechanisms of peroxygenase and peroxidase enzymes. FEBS Letters. 2002; 528:90–94. [PubMed: 12297285]
- Groves JT. The bioinorganic chemistry of iron in oxygenases and supramolecular assemblies. Proc Natl Acad Sci U S A. 2003; 100:3569–3574. [PubMed: 12655056]
- Wang Y, Hirao H, Chen H, Onaka H, Nagano S, Shaik S. Electron Transfer Activation of Chromopyrrolic Acid by Cytochrome P450 En Route to the Formation of an Antitumor Indolocarbazole Derivative: Theory Supports Experiment. J Am Chem Soc. 2008; 130:7170–7171. [PubMed: 18481854]

- 50. de Visser SP, Shaik S. A Proton-Shuttle Mechanism Mediated by the Porphyrin in Benzene Hydroxylation by Cytochrome P450 Enzymes. J Am Chem Soc. 2003; 125:7413–7424. [PubMed: 12797816]
- Passardi F, Theiler G, Zamocky M, Cosio C, Rouhier N, Teixera F, Margis-Pinheiro M, Ioannidis V, Penel C, Falquet L, Dunand C. PeroxiBase: The peroxidase database. Phytochem. 2007; 68:1605–1611.
- 52. Kunishima N, Fukuyama K, Wakabayashi S, Sumida M, Takaya M, Shibano Y, Amachi T, Matsubara H. Crystallization and preliminary X-ray diffraction studies of peroxidase from a fungus. Arthromyces ramosus Proteins: Struct Funct Bioinf. 1993; 15:216–220.
- 53. Patterson WR, Poulos TL. Crystal structure of recombinant pea cytosolic ascorbate peroxidase. Biochem. 1995; 34:4331–4341. [PubMed: 7703247]
- 54. Gajhede M, Schuller D, Henriksen A, Smith AT, Poulos TL. Crystal Structure of Horseradish Peroxidase C at 2.15 A resolution. Nat Struct Biol. 1997; 4:1032–1038. [PubMed: 9406554]
- Zámocký M, Furtmüller PG, Obinger C. Evolution of structure and function of Class I peroxidases. Arch Biochem Biophys. 2010; 500:45–57. [PubMed: 20371361]
- Valderrama, B. Deactivation of Hemeperoxidases by Hydrogen Peroxide: Focus on Compound III. In: Torres, E.; Ayala, M., editors. Biocatalysis Based on Heme Peroxidases. Springer-Verlab; Berlin Heidelberg: 2010.
- Feducia J, Dumarieh R, Gilvey LB, Smirnova T, Franzen S, Ghiladi RA. Characterization of Dehaloperoxidase Compound ES and Its Reactivity with Trihalophenols. Biochem. 2009; 48:995– 1005. [PubMed: 19187035]
- Gumiero A, Murphy E, Metcalfe CL, Moody P, Raven EL. An analysis of substrate binding interactions in the heme peroxidase enzymes: A structural perspective. Arch Biochem Biophys. 2010; 500:13–20. [PubMed: 20206594]



Figure 1.

A. The natural products lincomycin A, anthramycin (a PBD), and hormaomycin. **B.** The initial steps proposed for the biosynthesis of the hydropyrrole moiety found in lincomycin A, PBDs and hormaomycin. *Ortho*-hydroxylation of L-tyrosine to L-DOPA by Orf13 (*S. refuineus*), LmbB2 (*S. lincolnesis*) or HrmE (*S. griseoflavus*) is the first step of hydropyrrole moiety biosynthesis in the natural products anthramycin, lincomycin A and hormaomycin, respectively.



Figure 2.

UV-visible absorption spectrum of purified Orf13 (100% heme b occupancy) in 20 mM Tris-HCl (pH 8.0), 10 mM imidazole and 10% glycerol. Soret band of heme b is observed at 408 nm and Q-bands at 530 nm, 561 nm and 630 nm (inset).



Figure 3.

HPLC chromatograms for porphyrin detection. **A.** Supernatant of denatured Orf13 sample. **B.** Co-injection of the sample shown in **A** with heme b standard.



Figure 4.

A. UV-visible absorption spectrum of ferric-heme Orf13 (solid line) and ferrous-CO-heme (g) Orf13 (dashed line) with 100% heme b occupancy in 20 mM Tris-HCl (pH 8.0), 10 mM imidazole and 10% glycerol. **B.** X-band EPR spectrum of ferric-heme Orf13 at 15 K. Experimental conditions: 90 μ M Orf13 with 50% heme b occupancy (45 μ M heme b) in 10 mM sodium phosphate (pH 8.0) and 50% glycerol; frequency, 9.478 GHz; microwave power, 201 μ W; modulation frequency, 100 kHz; modulation amplitude, 10.0 G; receiver gain, 5×10^3 .



Figure 5.

UV-visible absorption spectra of Orf13 (100% heme b) **A.** Orf13 (4 μ M) in the absence (solid line) and presence (dashed line) of 500 μ M hydrogen peroxide in 100 mM sodium phosphate (pH 8.0) at room temperature; **B.** Orf13 with L-tyrosine followed by the addition of hydrogen peroxide. Final experimental conditions: 4 μ M Orf13, 5 mM L-tyrosine, 500 μ M hydrogen peroxide in 100 mM sodium phosphate (pH 8.0) at room temperature. The sample was scanned at 2 minute intervals for 10 minutes after the addition of hydrogen peroxide.





Proposed Mechanism for Ort/io-Hydroxylation of L-Tyrosine by Orf13

Table 1
Steady State Kinetic Parameters for L-Tyrosine Hydroxylation by Orf13 ^a

Variable Substrate	Fixed Substrate	$K_{\rm m}^{\ \ b}$ (mM)	k_{cat} (s ⁻¹)	$k_{\rm cat}/K_{\rm m} ({\rm M}^{-1}{\rm s}^{-1})$
L-Tyrosine	H_2O_2	0.45 ± 0.04	0.576 ± 0.005	$(1.2\pm0.1)\times10$
H_2O_2	L-Tyrosine	1.0 ± 0.3	1.5 ± 0.3	$(1.5\pm0.2)\times10$

^{*a*}Assays were performed at 37°C with 0.3 – 1 μ M Orf13 (75% heme b occupancy) in 100 mM sodium phosphate (pH 8.0). L-DOPA formation was measured using the L-DOPA colorimetric assay.

bThese values are apparent $K_{\rm m}$ constants at saturating concentrations of the other substrate. Mean and standard error are reported.

Assay Condition ^{<i>a</i>,<i>b</i>}	$k_{\rm obs} ({\rm min^{-1}})^{\mathcal{C}}$	Relative Percentage ^d
Orf13	None	0
$Orf13 + H_2O_2$	34 ± 4	100
$Orf13 + H_2O_2 - O_2$	33 ± 3	98
$Orf13 + H2O2 + catalase (75 \ \mu g/mL)$	1.6 ± 0.2	5
$Orf13 + H2O2 + SOD (100 \ \mu g/mL)$	26.5 ± 0.6	78
Orf13 + AscA	0.58 ± 0.01	1.7
$Orf13 + AscA - O_2$	None	0
$Orf13 + AscA + catalase (75 \ \mu g/mL)$	0.15 ± 0.01	0.5
$Orf13 + AscA + SOD~(100~\mu\text{g/mL})$	0.59 ± 0.1	1.7
Orf13 + DHFA	0.69 ± 0.06	2
$Orf13 + DHFA - O_2$	None	0
$Orf13 + DHFA + catalase~(75~\mu g/mL)$	None	0
$Orf13 + DHFA + SOD \; (100 \; \mu g/mL)$	None	0

 Table 2

 Reaction Dependence Behavior of Orf13 for L-Tyrosine Hydroxylation

^{*a*}Abbreviations: Tyrosine Hydroxylase (Orf13), hydrogen peroxide (H₂O₂), molecular oxygen (O₂), L-ascorbate (AscA), dihydroxyfumaric acid (DHFA), superoxide dismutase (SOD).

 b Final assay concentrations: 0.5 or 2.5 μ M Orf13 (75% heme b occupancy), 5 mM L-tyrosine in 100 mM sodium phosphate (pH 8.0) at 37°C; 25 mM AscA, 2 mM DHFA or 500 μ M H2O2 as indicated by assay condition. L-DOPA detected by L-DOPA colorimetric assay for H2O2 dependent reactions and by HPLC-FLD for AscA and DHFA dependent reactions.

^cMean and standard deviation reported for k_{obs}.

 d Relative percentage is based on Orf13 + H2O2 condition where maximal turnover is observed.